skip to navigation skip to content
 

Accelerate Plus

These ventures have been with Accelerate Cambridge for over six months and are looking at raising their seed round.

Anvil

 Anvil is a tool that takes the pain out of software development, without sacrificing power. Companies are best placed to know their own businesses and develop their own business process tools, but developing web applications is hugely slow and complicated. Anvil's visual designer, simple Python code environment and "batteries-included" philosophy makes business application development faster, easier and more agile.

Visit the Anvil website

Anvil logo

BioPhonics (formerly TunedIn Dx)

BioPhonics is developing consumer and medical devices to automatically detect abnormalities from bodily sounds. They have developed a prototype of an intelligent stethoscope capable of automatic detection of heart diseases. The company's mission is to produce innovative technology to improve early detection of diseases.

Visit the BioPhonics website

BioPhonics logo

Capito Systems

Capito Systems (est. 2012), also trading as capito.ai, specialises in the contextual understanding of natural language (NLU). We have built a high performance NLU cloud platform that delivers application-specific semantic understanding of free-form voice and text inputs at speed and scale. Applications include intelligent voice control, conversational interfaces like chat bots, and semantic search. Our technology is platform-independent and easy to integrate via our APIs. We are able to ‘bootstrap’ NLU models quickly using the latest machine learning techniques coupled with our streamlined development workflows in support of rapid prototyping & testing. Unlike other NLP/NLU solutions, including the “open developer platforms” offered by major players like Amazon, Microsoft and Facebook, ours is a premium NLU product customised for each use case by our in-house experts, as we seek to develop long-term relationships with our clients.

Visit the Capito Systems website

Capito.ai logo

Flit

Flit (formerly Hinton Bikes) is developing a new electric bike that is designed from the ground up to make it convenient for more people to cycle in our increasingly congested and polluted cities. It folds down small enough to take on a train, is light enough to carry upstairs, and is smart enough to tell you when to pump up your tyres. When you get home, simply drop it into its dock for charging. Our mission is to make riding a bike more convenient and reliable than driving a car so that we can get more people cycling in our cities.

Visit the Flit website

Flit logo

Pexxi (formerly Sura)

Pexxi is a personal medicine platform that tailors and monitors oral contraceptive use based on every woman's unique biological profile; medical history, mental health, genetics and hormone levels.

Visit the Pexxi website

Pexxi logo

PHARMeNABLE

PharmEnable explores new areas of chemical space that no one else is currently searching to enable the development of vital new medicines.

Visit the PHARMeNABLE website

Pharmenable logo

POCKiT diagnostics

Stroke affects 16,000,000 people each year. 33 per cent of patients will die and 90 per cent of survivors will have a disability for the rest of their lives. POCKiT diagnostics have discovered a novel biomarker panel that could increase stroke patient treatment from 4 per cent to 40 per cent. We are leading a £1,000,000 grant from the United Kingdom government to finish an extensive clinical study in order to achieve regulatory approval. Our goal is to achieve market approval in 2020.

Visit the POCKiT diagnostics website

Pockit diagnostics logo

PostEra

PostEra is the first company to algorithmically complete the ‘design-make-test’ cycle of drug discovery. Our machine learning methods iteratively design the best drug candidates, decide how to make them, and test the compounds using the most informative experiments. With this new technology, we can search new areas of chemical space hitherto unexplored. Furthermore, incorporation of model uncertainty allows our algorithms to be aware of their own limitations, allowing for safer and more cost-effective predictions when compounds must be synthesised and experimentally verified. Ultimately, these novel approaches allow us to industrialise the traditionally artisanal field of drug discovery.

PostEra logo.

SmartBell

Smartbell offers a simple precision agriculture solution for livestock rearing and management. The Smartbell system implements a fully-automated solution for livestock management, including distress alerts, herd analysis and customised farm management reports. Using advanced analytics on data gathered from animal wearables, Smartbell also cross references regional data to better understand resource utilisation and promote proven best practices.

Watch the SmartBell team in discussion with Luther Phillips

Visit the Smartbell website

Smartbell logo

SPIREA

SPIREA is a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

The technology is based on biodegradable polymeric formulations of a combination of drugs for targeted and sustained release that will ultimately improve the efficacy and safety of treatments and patient compliance and comfort. This means a simpler, safer and more effective treatment for various diseases and a pioneering strategy in the management of diseases by combination therapy.

SPIREA aims to establish the polymer platform as a major player in the drug delivery space by partnering with pharmaceutical and biotech companies.

SPIREA logo

Spotta

Spotta intends to be the world leader in smart pest detection. Our core technology is an ultra-low-power, insect monitoring sensor that can detect infestations early. By allowing earlier, cheaper intervention we aim to put a significant dent in the global $70 billion annual cost of invasive insect pests.

Visit the Spotta website

Spotta logo.

Swift Molecular Diagnostics

Swift Molecular Diagnostics have created a novel technology that allows the development of self-contained diagnostic devices for the fast, accurate and low-cost genetic detection that do not require laboratory facilities or trained personnel.

We have filed the patent application of our technology and we aim in the first instance to implement our technology to detect antibiotic resistance from patients, allowing the effective treatment of bacterial infections and fast response in acute cases such as bacteraemia and septicaemia.

Watch the Swift Molecular Diagnostics team in discussion with Luther Phillips

Visit the Swift Molecular Diagnostics website

SwiftDX